A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

Trial Profile

A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Diacerein (Primary) ; Febuxostat
  • Indications Gout
  • Focus Proof of concept; Therapeutic Use
  • Sponsors TWi Biotechnology
  • Most Recent Events

    • 05 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2016 According to a TWi Biotechnology, Inc., media release, the Company expects to report top-line results from this study in the fourth quarter of 2016.
    • 27 Jun 2016 Status changed from recruiting to active, no longer recruiting, according to a TWi Biotechnology, Inc., media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top